Hemophilia A

New England CEPAC

The Institute for Clinical and Economic Review (ICER) will develop a report assessing the comparative clinical effectiveness and value of emicizumab (Hemlibra®, Genentech), a monoclonal antibody currently under review by the FDA for prevention of bleeding in patients who have hemophilia A with coagulation factor VIII inhibitors. Factor VIII is the clotting protein that is deficient in hemophilia A, and inhibitors interfere with factor replacement therapy. Emicizumab was approved by the FDA in November of 2017.

Associated Meetings

March 29, 2018 10am-4pm ET

Boston Marriott Cambridge
50 Broadway
Cambridge, MA, 02142

The New England CEPAC will convene to review the comparative clinical effectiveness and value of emicizumab for treatment of hemophilia A.


Key Dates

Associated Materials

08/11/2017

08/11/2017 – 09/06/2017

09/11/2017

09/11/2017 – 09/29/2017

10/10/2017

11/21/2017

11/21/2017

01/26/2018

01/26/2018

Open to public comment until February 23, 2018 at 5pm ET. For more information on submitting a public comment, visit our engagement page.